Open Orphan plc was founded in 2017 and is a rapidly growing niche CRO pharmaceutical services company. Open Orphan is listed on both the London and Dublin stock exchanges (ORPH), and is led by a leadership team with extensive industry and financial expertise. In June 2019 Open Orphan completed a reverse takeover of Venn Life Sciences and in January 2020 it completed the merger with hVIVO.
Open Orphan comprises of two commercial specialist CRO services businesses, hVIVO and Venn and is developing an early stage orphan drug genomics data platform business. This platform captures valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools.
hVIVO is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe’s only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data. The Company has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, hVIVO is rapidly advancing a number of Coronavirus challenge study models.
Read more about Open Orphan’s contributions to the fight against COVID-19 here